In this review:
177Lu-PSMA-617 radioligand therapy active in mCRPC
SOC + AA or docetaxel with prednisolone
AA + prednisone added to ADT improves PROs
Docetaxel + AS for PSA relapse after RP and/or RT
BRCA2 mutations linked to poor outcomes in mCRPC
DNA repair gene panel mutations in PrCa cases
Prednisone→dexamethasone in mCRPC after AA + prednisone
Detecting DNA DDR alterations in ctDNA vs tumour tissue
Neuropsychiatric AEs of enzalutamide and AA + prednisone
Please login below to download this issue (PDF)